Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 1, 2006, Pages 85-92

  Colao, Annamaria ^b   Attanasio, Roberto ^c   Pivonello, Rosario ^b   Cappabianca, Paolo ^a   Cavallo, Luigi M ^a   Lasio, Giovanni ^b   Lodrini, Alessandro ^d   Lombardi, Gaȩtano ^d   Cozzi, Renato ^c  

^a Department of Molecular and Clinical Endocrinology and Oncology and Neurological Sciences   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN;

ACROMEGALY; ADULT; ALGORITHM; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GROWTH HORMONE RELEASE; GROWTH HORMONE SECRETING CELL; HUMAN; HYPOPHYSIS FUNCTION; HYPOPHYSIS TUMOR; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

ACROMEGALY; ADENOMA; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMAN GROWTH HORMONE; HUMANS; HYPOPHYSECTOMY; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OCTREOTIDE; PEPTIDES, CYCLIC; PITUITARY NEOPLASMS; RETROSPECTIVE STUDIES; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 30344441806     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-1208     Document Type: Article

References (34)

1. Orme SM, McNally RJQ, Cartwright RA, Belchetz PE, United Kingdom Acromegaly Study Group 1998 Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab 83:2730-2734
2. Holdaway IM, Rajasoorya CR, Gamble GD 2004 Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667-674
3. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS 2004 Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 89:1613-1617
4. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki VJ, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman U-H, Viikari J, Voutilainen E 2005 A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90:4081-4086
5. Swearingen B, Barker FG, Katznelson L, Biller BMK, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT 1998 Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419-3426
6. Beauregard C, Truong U, Hardy J, Serri O 2003 Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 58:86-91
7. Colao A, Ferone D, Marzullo P, Lombardi G 2004 Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr Rev 25:102-152
8. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, von Werder K, Wass J, Giustina A, for the Acromegaly Treatment Consensus Workshop Participants 2002 Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054-4058
9. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook L, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL 1998 Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 83:3034-3040
10. Sheppard MC 2003 Primary medical therapy for acromegaly. Clin Endocrinol (Oxf) 58:387-399
11. Colao A, Ferone D, Cappabianca P, del Basso De Caro ML, Marzullo P, Monticelli A, Alfieri A, Merola B, Cali A, de Divitiis E, Lombardi G 1997 Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 82:3308-3314
12. Ben-Shlomo A, Melmed S 2003 The role of pharmacotherapy in perioperative management of patients with acromegaly. J Clin Endocrinol Metab 88:963-968
13. Bevan JS 2005 The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90:1856-1863
14. Melmed S, Stemberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance M-L, Rhew D, Kleinberg D, Barkan A 2005 A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90:4405-4410
15. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G 2001 Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86:2779-2786
16. Freda PU 2002 Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87:3013-3018
17. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM 2003 Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 88:3090-3098
18. Attanasio R, Baldelli R, Pivonello R, Grottoli S, Bocca L, Gasco V, Giusti M, Tambunano G, Colao A, Cozzi R 2003 Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab 88:5258-5265
19. Petrossians P, Martins LB, Espinoza C, Daly A, Betea D, Valdes-Socin H, Stevenaert A, Chanson P, Beckers A 2005 Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 152:1-7
20. Ahmed S, Elsheikh M, Page RCL, Adams CBT, Wass JAH 1999 Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf) 50:561-567
21. Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JRE, Shalet SM 1998 The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone secreting adenomas. Clin Endocrinol (Oxf) 49:653-657
22. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S 2000 Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526-529
23. Colao A, Lombardi G 1998 Growth hormone and prolactin excess. Lancet 352:1455-1461
24. Stewart PM, Stewart SE, Clark PM, Sheppard MC 1999 Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR). Clin Endocrinol (Oxf) 50:295-299
25. Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Santo A, Longobardi S, Merola B, Salvatore M, Lombardi G 1996 Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 81:2356-2362
26. Lamberts SW, de Herder WW, van der Lely AJ 1998 Pituitary insufficiency. Lancet 352:127-134
27. Nomikos P, Buchfelder M, Fahlbusch R 2005 The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure.' Eur J Endocrinol 152:379-387
28. Freda PU, Wardlaw SL, Post KD 1998 Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 89:353-358
29. De P, Rees DA, Davies N, John R, Neal J, Mills RG, Vafidis J, Davies JS, Scanlon MF 2003 Transsphenoidal surgery for acromegaly in Wales: results based on stringent criteria of remission. J Clin Endocrinol Metab 88:3567-3572
30. Kreutzer J, Vance ML, Lopes MB, Laws Jr ER 2001 Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 86:4072-4077
31. Sheaves R, Jenkins P, Blackburn P, Huneidi AH, Afshar F, Medbak S, Grossman AB, Besser GM, Wass JA 1996 Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol (Oxf) 45:407-413
32. Chanson P, Leselbaum A, Blumberg J, Schaison G 2000 Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly. Pituitary 2:269-276
33. Didoni G, Grottoli S, Gasco V, Battistini M, Ferone D, Giusti M, Ragazzoni F, Ruffo P, Ghigo E, Minuto F 2004 Cost-of-illness study in acromegalic patients in Italy. J Endocrinol Invest 27:1034-1039
34. Attanasio R, Epaminonda P, Motti, E Giugni E, Ventrella L, Cozzi R, Farabola M, Loli P, Beck-Peccoz P, Arosio M 2003 γ-Knife radiosurgery in acromegaly: a 4-year-follow-up study. J Clin Endocrinol Metab 88:3105-3131